References
- Feldstein C, Akopian M, Olivieri AO, Garrido D. Association between nondipper behavior and serum calcium in hypertensive patients with mild-to-moderate chronic renal dysfunction. Clin Exp Hypertens 2012;34:417–23
- Kawai T, Ohishi M, Onishi M, et al. Cut-off value of brachial-ankle pulse wave velocity to predict cardiovascular disease in hypertensive patients: a cohort study. J Atheroscler Thromb 2013;20:391–400
- Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; Cardio Ankle Vascular Index (CAVI). J Atheroscler Thromb 2006;13:101–7
- Shirai K. Analysis of vascular function using the cardio-ankle vascular index (CAVI). Hypertens Res 2011;34:684–5
- Nakamura K, Tomaru T, Yamamura S, et al. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J 2008;72:598–604
- Takaki A, Ogawa H, Wakeyama T, et al. Cardio-ankle vascular index is a new noninvasive parameter of arterial stiffness. Circ J 2007;71:1710–14
- Nakamura K, Iizuka T, Takahashi M, et al. Association between cardio-ankle vascular index and serum cystatin C levels in patients with cardiovascular risk factor. J Atheroscler Thromb 2009;16:371–9
- Masugata H, Senda S, Okuyama H, et al. Comparison of central blood pressure and cardio-ankle vascular index for association with cardiac function in treated hypertensive patients. Hypertens Res 2009;32:1136–42
- Ibata J, Sasaki H, Kakimoto T, et al. Cardio-ankle vascular index measures arterial wall stiffness independent of blood pressure. Diabetes Res Clin Pract 2008;80:265–70
- Miyashita Y, Endo K, Saiki A, et al. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2009;16:539–45
- Noike H, Nakamura K, Sugiyama Y, et al. Changes in cardio-ankle vascular index in smoking cessation. J Atheroscler Thromb 2010;17:517–25
- Wallerson DC, Devereux RB. Reproducibility of echocardiographic left ventricular measurements. Hypertension 1987;9:II6–18
- Miyashita Y, Saiki A, Endo K, et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb 2009;16:621–6
- Hashimoto J, Nichols WW, O'Rourke MF, Imai Y. Association between wasted pressure effort and left ventricular hypertrophy in hypertension: influence of arterial wave reflection. Am J Hypertens 2008;21:329–33
- Hashimoto J, Westerhof BE, Westerhof N, et al. Different role of wave reflection magnitude and timing on left ventricular mass reduction during antihypertensive treatment. J Hypertens 2008;26:1017–24
- Tomiyama H, Yamashina A. CAVI vs. pressure and stiffness gradients in the arterial tree. Hypertens Res 2010;33:380
- Lee HY, Oh BH. Aging and arterial stiffness. Circ J 2010;74:2257–62
- Oyekan A. PPARs and their effects on the cardiovascular system. Clin Exp Hypertens 2011;33:287–93
- Maeda A, Tamura K, Kanaoka T, et al. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY). Clin Exp Hypertens 2012;34:249–57
- Ohbayashi H, Miyazawa C, Miyamoto K, et al. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb 2009;16:490–500